The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world clinicopathological and molecular characteristics, treatment patterns, and outcomes in patients with KRAS G12C–mutated metastatic colorectal cancer in AACR Project GENIE.
 
Hil Hsu
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Research Funding - Amgen
 
Shivani Aggarwal
Employment - Amgen; IQvia; Regeneron
Stock and Other Ownership Interests - Regeneron
 
Archana Balan
No Relationships to Disclose
 
Biagio Ricciuti
No Relationships to Disclose
 
Jacklynn V. Egger
No Relationships to Disclose
 
Michele LeNoue-Newton
Employment - DaVita (I)
Stock and Other Ownership Interests - DaVita (I); General Electric (I)
Research Funding - GE Healthcare (Inst)
 
Marilyn Elaine Holt
Employment - HCA/Sarah Cannon
Research Funding - GenomOncology (Inst)
 
Jocelyn Lee
Stock and Other Ownership Interests - Abbott; Gilead Sciences; Qiagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
 
Victoria M. Chia
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Emily Chan
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Marko Rehn
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Xuena Wang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Christine M. Lovly
Honoraria - Amgen; AstraZeneca; Blueprint Medicines; Cepheid; D2G Oncology; Daiichi Sankyo/Astra Zeneca; EMD Serono; Foundation Medicine; Genentech; Janssen Oncology; Lilly; Pfizer; Puma Biotechnology; Syros Pharmaceuticals; Syros Pharmaceuticals; Takeda
Research Funding - AstraZeneca (Inst); Novartis; Xcovery
(OPTIONAL) Uncompensated Relationships - Johnson & Johnson/Janssen; Roche/Genentech
 
Gregory J. Riely
Research Funding - GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Other Relationship - Mirati Therapeutics; Pfizer; Roche/Genentech; Takeda
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Archer; ARIAD; AstraZeneca; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; EMD Serono; Foundation Medicine; Genentech; Gilead Sciences; Gritstone Bio; Hengrui Therapeutics; Instil Bio; Janssen Oncology; Maverick Therapeutics; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Panasonic; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)
 
Valsamo Anagnostou
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)